- Advanced search
- Immuno Portal
- Malaria Portal
|No information available.|
|Summary of Clinical Use|
|Secukinumab is approved by the US FDA for the treatment of plaque psoriasis.
Secukinumab also met its clinical endpoints in Phase III clinical trial for ankylosing spondylitis (NCT01649375) , and was FDA approved for this indication and psoriatic arthritis [7-8] in January 2016.
The antibody is also in Phase II clinical trial for multiple sclerosis (NCT01874340) based on results from experiments in an animal model of the disease (experimental autoimmune encephalomyelitis, EAE) and in vitro human cell assays .
|Mechanism Of Action and Pharmacodynamic Effects|
|Secukinumab targets proinflammatory interleukin (IL)-17A  which is released by T helper 17 cells , and is a validated molecular target for the treatment of chronic immune diseases . Antibody neutralisation of circulating IL-17A reduces symptoms in autoimmune diseases such as plaque psoriasis [6,9], rheumatoid arthritis (note that clinical trial results have not shown significant improvement over placebo ), and chronic noninfectious uveitis.|
For extended ADME data see the following:
Electronic Medicines Compendium (eMC)
European Medicines Agency (EMA)